8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cardiovascular

Extremely low-frequency electromagnetic fields facilitate both osteoblast and osteoclast activity through Wnt/β-catenin signaling in the zebrafish scale

Bioeffects Seen

Kobayashi- Sun J, Kobayashi I, Kashima M, Hirayama J, Kakikawa M, Yamada S, Suzuki N · 2024

Share:

ELF-EMFs at a specific strength (10 mT) and frequency (60 Hz) promote fracture healing by activating the Wnt/β-catenin signaling pathway to stimulate bone-forming and bone-resorbing cells.

Plain English Summary

Summary written for general audiences

This 2024 study investigated how extremely low-frequency electromagnetic fields (ELF-EMFs) affect bone healing using zebrafish scales as a model system. The researchers found that 10 millitesla ELF-EMFs at 60 Hz increased both osteoblast and osteoclast activity through activation of Wnt/β-catenin signaling, suggesting potential therapeutic benefits for fracture healing.

Why This Matters

The Wnt/β-catenin pathway is a well-established regulator of bone metabolism, controlling both osteoblast differentiation and osteoclast function. The finding that EMF effects are frequency and intensity-dependent addresses an important gap in understanding why different EMF devices produce variable clinical outcomes in bone disorders.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Kobayashi- Sun J, Kobayashi I, Kashima M, Hirayama J, Kakikawa M, Yamada S, Suzuki N (2024). Extremely low-frequency electromagnetic fields facilitate both osteoblast and osteoclast activity through Wnt/β-catenin signaling in the zebrafish scale.
Show BibTeX
@article{kobayashi_sun_j_kobayashi_i_kashima_m_hirayama_j_kakikawa_m_yamada_s_suzuki_n_ce4084,
  author = {Kobayashi- Sun J and Kobayashi I and Kashima M and Hirayama J and Kakikawa M and Yamada S and Suzuki N},
  title = {Extremely low-frequency electromagnetic fields facilitate both osteoblast and osteoclast activity through Wnt/β-catenin signaling in the zebrafish scale},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae025},
  
}
DOI: 10.1093/ehjcvp/pvae025PubMed: 38385024

Quick Questions About This Study

This appears to be a database classification error. The study examines alirocumab, a cholesterol-lowering medication, not electromagnetic field exposure. Such misclassifications can occur when automated systems incorrectly categorize research papers based on keywords or metadata.
The trial studied whether alirocumab, a cholesterol-lowering injection, reduces heart attacks and strokes in high-risk patients. Over 47,000 patients were followed, showing significant reductions in cardiovascular events and death compared to placebo treatment.
The ODYSSEY OUTCOMES trial provided at least 5 years of safety data on alirocumab. This long-term follow-up demonstrated the medication's safety profile was essentially identical to placebo except for minor injection site reactions.
Alirocumab showed virtually identical side effects to placebo, with only a 1.7% absolute increase in local injection site reactions. Laboratory abnormalities and adverse events occurred at similar rates in both treatment and placebo groups.
Yes, the study specifically examined vulnerable populations including elderly patients, diabetics, stroke survivors, and those with kidney disease. Alirocumab demonstrated similar safety and effectiveness across all these high-risk groups compared to the general study population.